A detailed history of Emc Capital Management transactions in Exelixis, Inc. stock. As of the latest transaction made, Emc Capital Management holds 9,961 shares of EXEL stock, worth $263,966. This represents 0.13% of its overall portfolio holdings.

Number of Shares
9,961
Previous 9,961 -0.0%
Holding current value
$263,966
Previous $236,000 5.08%
% of portfolio
0.13%
Previous 0.14%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 20, 2024

SELL
$20.17 - $23.93 $16,398 - $19,455
-813 Reduced 7.55%
9,961 $236,000
Q3 2023

Nov 09, 2023

BUY
$19.04 - $22.74 $130,652 - $156,041
6,862 Added 175.41%
10,774 $235,000
Q2 2023

Aug 14, 2023

SELL
$18.17 - $20.48 $124,682 - $140,533
-6,862 Reduced 63.69%
3,912 $223,000
Q4 2022

Feb 13, 2023

BUY
$14.96 - $17.39 $73,348 - $85,263
4,903 Added 83.51%
10,774 $173,000
Q2 2022

Aug 12, 2022

BUY
$17.44 - $23.16 $34,688 - $46,065
1,989 Added 51.24%
5,871 $122,000
Q1 2022

May 16, 2022

BUY
$17.03 - $22.67 $66,110 - $88,004
3,882 New
3,882 $87,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $8.53B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Emc Capital Management Portfolio

Follow Emc Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Emc Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Emc Capital Management with notifications on news.